A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination with Nab-Paclitaxel and Gemcitabine in Patients with Previously Untreated Stage IV Pancreatic Cancer
S
Safi Shahda, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Not Recruiting
18 years - 90 years
All
Phase
N/A
1 Location
Brief description of study
The purpose of this study is to evaluate the safety and tolerability of vantictumab in combination with nab-paclitaxel and gemcitabine in patients with sreviously untreated Stage IV pancreatic cancer.
Detailed description of study
The purpose of this study is to evaluate the safety and tolerability of vantictumab in combination with nab-paclitaxel and gemcitabine in patients with sreviously untreated Stage IV pancreatic cancer.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Pancreatic Cancer
-
Age: 18 years - 90 years
-
Gender: All
Updated on
01 Aug 2024.
Study ID: 1308051009
